174 related articles for article (PubMed ID: 35342308)
1. Safety in Japanese Advanced Breast Cancer Patients Who Received Abemaciclib in MONARCH 2 and MONARCH 3: Assessment of Treatment-Emergent Neutropenia, Diarrhea, and Increased Alanine Aminotransferase and Aspartate Aminotransferase Levels.
Masuda N; Chen Y; Kawaguchi T; Dozono K; Toi M
Cancer Manag Res; 2022; 14():1179-1194. PubMed ID: 35342308
[TBL] [Abstract][Full Text] [Related]
2. Management of Abemaciclib-Associated Adverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3.
Rugo HS; Huober J; García-Sáenz JA; Masuda N; Sohn JH; Andre VAM; Barriga S; Cox J; Goetz M
Oncologist; 2021 Jan; 26(1):e53-e65. PubMed ID: 32955138
[TBL] [Abstract][Full Text] [Related]
3. Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
Takahashi M; Tokunaga E; Mori J; Tanizawa Y; van der Walt JS; Kawaguchi T; Goetz MP; Toi M
Breast Cancer; 2022 Jan; 29(1):174-184. PubMed ID: 34661821
[TBL] [Abstract][Full Text] [Related]
4. Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials.
Toi M; Inoue K; Masuda N; Iwata H; Sohn J; Hae Park I; Im SA; Chen SC; Enatsu S; Turner PK; André VAM; Hardebeck MC; Sakaguchi S; Goetz MP; Sledge GW
Cancer Sci; 2021 Jun; 112(6):2381-2392. PubMed ID: 33686753
[TBL] [Abstract][Full Text] [Related]
5. Japanese subpopulation analysis of MONARCH 2: phase 3 study of abemaciclib plus fulvestrant for treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer that progressed on endocrine therapy.
Inoue K; Masuda N; Iwata H; Takahashi M; Ito Y; Miyoshi Y; Nakayama T; Mukai H; van der Walt JS; Mori J; Sakaguchi S; Kawaguchi T; Tanizawa Y; Llombart-Cussac A; Sledge GW; Toi M
Breast Cancer; 2021 Sep; 28(5):1038-1050. PubMed ID: 33797023
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials.
Goetz MP; Okera M; Wildiers H; Campone M; Grischke EM; Manso L; André VAM; Chouaki N; San Antonio B; Toi M; Sledge GW
Breast Cancer Res Treat; 2021 Apr; 186(2):417-428. PubMed ID: 33392835
[TBL] [Abstract][Full Text] [Related]
7. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer.
Goetz MP; Toi M; Campone M; Sohn J; Paluch-Shimon S; Huober J; Park IH; Trédan O; Chen SC; Manso L; Freedman OC; Garnica Jaliffe G; Forrester T; Frenzel M; Barriga S; Smith IC; Bourayou N; Di Leo A
J Clin Oncol; 2017 Nov; 35(32):3638-3646. PubMed ID: 28968163
[TBL] [Abstract][Full Text] [Related]
8. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy.
Sledge GW; Toi M; Neven P; Sohn J; Inoue K; Pivot X; Burdaeva O; Okera M; Masuda N; Kaufman PA; Koh H; Grischke EM; Frenzel M; Lin Y; Barriga S; Smith IC; Bourayou N; Llombart-Cussac A
J Clin Oncol; 2017 Sep; 35(25):2875-2884. PubMed ID: 28580882
[TBL] [Abstract][Full Text] [Related]
9. Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study.
Tolaney SM; Beeram M; Beck JT; Conlin A; Dees EC; Puhalla SL; Rexer BN; Burris HA; Jhaveri K; Helsten T; Becerra C; Kalinsky K; Moore KN; Manuel AM; Lithio A; Price GL; Chapman SC; Litchfield LM; Goetz MP
Front Oncol; 2021; 11():810023. PubMed ID: 35223458
[TBL] [Abstract][Full Text] [Related]
10. Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial.
Neven P; Rugo HS; Tolaney SM; Iwata H; Toi M; Goetz MP; Kaufman PA; Lu Y; Haddad N; Hurt KC; Sledge GW
Breast Cancer Res; 2021 Aug; 23(1):87. PubMed ID: 34425869
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study.
Rugo HS; O'Shaughnessy J; Boyle F; Toi M; Broom R; Blancas I; Gumus M; Yamashita T; Im YH; Rastogi P; Zagouri F; Song C; Campone M; San Antonio B; Shahir A; Hulstijn M; Brown J; Zimmermann A; Wei R; Johnston SRD; Reinisch M; Tolaney SM;
Ann Oncol; 2022 Jun; 33(6):616-627. PubMed ID: 35337972
[TBL] [Abstract][Full Text] [Related]
12. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer.
Johnston S; Martin M; Di Leo A; Im SA; Awada A; Forrester T; Frenzel M; Hardebeck MC; Cox J; Barriga S; Toi M; Iwata H; Goetz MP
NPJ Breast Cancer; 2019; 5():5. PubMed ID: 30675515
[TBL] [Abstract][Full Text] [Related]
13. A Randomized Phase I Study of Abemaciclib in Chinese Patients with Advanced and/or Metastatic Cancers.
Zhang J; Yang N; Ji D; Shen W; Li W; Han R; Wang N; Tao H; Chapman SC; Sykes AK; Zhang W; Hu X
Target Oncol; 2021 Mar; 16(2):177-187. PubMed ID: 33492568
[TBL] [Abstract][Full Text] [Related]
14. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
Tolaney SM; Wardley AM; Zambelli S; Hilton JF; Troso-Sandoval TA; Ricci F; Im SA; Kim SB; Johnston SR; Chan A; Goel S; Catron K; Chapman SC; Price GL; Yang Z; Gainford MC; André F
Lancet Oncol; 2020 Jun; 21(6):763-775. PubMed ID: 32353342
[TBL] [Abstract][Full Text] [Related]
15. Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine Therapy.
Franzoi MA; Eiger D; Ameye L; Ponde N; Caparica R; De Angelis C; Brandão M; Desmedt C; Di Cosimo S; Kotecki N; Lambertini M; Awada A; Piccart M; Azambuja E
J Natl Cancer Inst; 2021 Apr; 113(4):462-470. PubMed ID: 32750143
[TBL] [Abstract][Full Text] [Related]
16. Abemaciclib plus fulvestrant in East Asian women with HR+, HER2- advanced breast cancer: Overall survival from MONARCH 2.
Toi M; Huang CS; Im YH; Sohn J; Zhang W; Sakaguchi S; Haddad N; van Hal G; Sledge GW
Cancer Sci; 2023 Jan; 114(1):221-226. PubMed ID: 36168844
[TBL] [Abstract][Full Text] [Related]
17. Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer.
Tamura K
Jpn J Clin Oncol; 2019 Dec; 49(11):993-998. PubMed ID: 31665472
[TBL] [Abstract][Full Text] [Related]
18. Quality of life with ribociclib
Rugo HS; Harmer V; O'Shaughnessy J; Jhaveri K; Tolaney SM; Cardoso F; Bardia A; Maheshwari VK; Tripathi S; Haftchenary S; Pathak P; Fasching PA
Ther Adv Med Oncol; 2023; 15():17588359231152843. PubMed ID: 36861085
[TBL] [Abstract][Full Text] [Related]
19. Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer.
Fujiwara Y; Tamura K; Kondo S; Tanabe Y; Iwasa S; Shimomura A; Kitano S; Ogasawara K; Turner PK; Mori J; Asou H; Chan EM; Yamamoto N
Cancer Chemother Pharmacol; 2016 Aug; 78(2):281-8. PubMed ID: 27312735
[TBL] [Abstract][Full Text] [Related]
20. Prediction of severe neutropenia and diarrhoea in breast cancer patients treated with abemaciclib.
Modi ND; Abuhelwa AY; Badaoui S; Shaw E; Shankaran K; McKinnon RA; Rowland A; Sorich MJ; Hopkins AM
Breast; 2021 Aug; 58():57-62. PubMed ID: 33906086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]